
...

### Data collation:
 inclusion criteria: (1) Hepatocellular carcinoma (HCC) selected using ICD-O-3 histological codes (8170-3, 8171-3, 8172-3, 8173-3, 8174-3, 8175-3); (2) HCC patients without cirrhosis (Ishak 0-4; No to moderate fibrosis; METAVIR F0-F3; Batt-Ludwig 0-3). 

### Exclusion criteria: 
* (1) Race information unknown 
* (2) Marital information unknown 
* (3) Age less than 19 years or more than 100 years 
* (4) Non-first primary tumor 
* (5) Not pathologically confirmed by microscopy 
* (6) Histological grade unknown 
* (7) SEER grade unknown 
* (8) T, N, M stage unknown 
* (9) Surgical information unknown
* (10) Tumor size unknown 
* (11) Survival information unknown. 


A total of 15 covariates were selected for analysis in this study, namely age, marital status, gender, race, AFP, radiotherapy, chemotherapy, systemic therapy, surgery, T stage, N stage, M stage, AJCC stage, tumor size and histologic grade. All patients were staged according to AJCC 8th edition. 

The patients were categorized into three groups based on the RX Summ–Surg Prim Site (1998+) field. These groups include: 

	a/README.md		b/README.md
	...		...
8		8
9	### Data collation:	9	### Data collation:
10	inclusion criteria: (1) Hepatocellular carcinoma (HCC) selected using ICD-O-3 histological codes (8170-3, 8171-3, 8172-3, 8173-3, 8174-3, 8175-3); (2) HCC patients without cirrhosis (Ishak 0-4; No to moderate fibrosis; METAVIR F0-F3; Batt-Ludwig 0-3).	10	inclusion criteria: (1) Hepatocellular carcinoma (HCC) selected using ICD-O-3 histological codes (8170-3, 8171-3, 8172-3, 8173-3, 8174-3, 8175-3); (2) HCC patients without cirrhosis (Ishak 0-4; No to moderate fibrosis; METAVIR F0-F3; Batt-Ludwig 0-3).
11		11
12	### Exclusion criteria:	12	### Exclusion criteria:
13	*(1) Race information unknown	13	* (1) Race information unknown
14	*(2) Marital information unknown	14	* (2) Marital information unknown
15	*(3) Age less than 19 years or more than 100 years	15	* (3) Age less than 19 years or more than 100 years
16	*(4) Non-first primary tumor	16	* (4) Non-first primary tumor
17	*(5) Not pathologically confirmed by microscopy	17	* (5) Not pathologically confirmed by microscopy
18	*(6) Histological grade unknown	18	* (6) Histological grade unknown
19	*(7) SEER grade unknown	19	* (7) SEER grade unknown
20	*(8) T, N, M stage unknown	20	* (8) T, N, M stage unknown
21	*(9) Surgical information unknown	21	* (9) Surgical information unknown
22	*(10) Tumor size unknown	22	* (10) Tumor size unknown
23	*(11) Survival information unknown.	23	* (11) Survival information unknown.
24		24
25		25
26	A total of 15 covariates were selected for analysis in this study, namely age, marital status, gender, race, AFP, radiotherapy, chemotherapy, systemic therapy, surgery, T stage, N stage, M stage, AJCC stage, tumor size and histologic grade. All patients were staged according to AJCC 8th edition.	26	A total of 15 covariates were selected for analysis in this study, namely age, marital status, gender, race, AFP, radiotherapy, chemotherapy, systemic therapy, surgery, T stage, N stage, M stage, AJCC stage, tumor size and histologic grade. All patients were staged according to AJCC 8th edition.
27		27
28	The patients were categorized into three groups based on the RX Summ–Surg Prim Site (1998+) field. These groups include:	28	The patients were categorized into three groups based on the RX Summ–Surg Prim Site (1998+) field. These groups include: